During the projected period, the global submucosal lifting agent market is expected to grow at a CAGR of 6.9%. The market value is projected to increase from USD 114.2 million in 2023 to USD 222.6 million by 2033. The global market was valued at USD 106.9 million at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 6.8% in 2023.
Market Outlook
Key Market Attributes
| Attributes | Details |
|---|---|
| Market Size, 2022 | USD 106.9 Million |
| Market Size, 2023 | USD 114.2 Million |
| Market Size, 2033 | USD 222.6 Million |
| Value CAGR (2023 to 2033) | 6.9% |
The market for submucosal lifting agents includes specific medical goods required for endoscopic procedures. These substances establish a safe separation between the mucosal and muscle layers of the gastrointestinal tract. This allows for more exact vision and less invasive treatment of diseases such as gastrointestinal bleeding, tumors, and polyps.
The rising prevalence of gastrointestinal illnesses, technical developments in endoscopy and increased knowledge about early detection, needs are all driving market expansion. Submucosal lifting agents play an important role in supporting successful and safe treatments, adding to the growth of the market as healthcare infrastructure expands and innovation continues.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global submucosal lifting agent market recorded a historic CAGR of 6.4% in the last 5 years from 2017 to 2022. The market value for the submucosal lifting agent market was around 30.8% of the overall USD 347.0 million of the global endoscopic submucosal dissection market.
Semi Annual Market Update
| Particular | Value CAGR |
|---|---|
| H1 | 6.00% (2022 to 2032) |
| H2 | 7.93% (2022 to 2032) |
| H1 | 6.30% (2023 to 2033) |
| H2 | 7.51% (2023 to 2033) |
The increasing demand for minimally invasive surgical procedures and devices is driving the expansion of the submucosal lifting agent market. By providing less traumatic alternatives to standard surgical approaches, minimally invasive techniques have changed the medical world. Smaller incisions, less tissue damage, faster recovery times, and less postoperative pain for patients are all benefits of these operations.
Submucosal injection fluids are critical in improving the efficacy of minimally invasive endoscopic treatments. These agents improve visualization and access for healthcare workers during treatments such as polypectomies, resections, and lesion removal by generating a regulated gap between tissue layers. The use of submucosal lifting agents improves precision and lowers the likelihood of problems.
The submucosal lifting agent market is expected to develop as the demand for minimally invasive procedures rises due to patient preferences for faster recovery and better outcomes. By establishing ideal procedural circumstances, these agents support the goals of minimally invasive operations. Also, advances in the formulations and applications of submucosal lifting agents fit with the ongoing evolution of minimally invasive surgical methods.
In essence, the interaction between minimally invasive surgical devices with submucosal lifting agents creates a positive feedback loop, pushing the expansion of both sectors as they meet the growing demand for improved, patient-friendly medical techniques.
The rising prevalence of gastrointestinal problems like upper gastrointestinal bleeding, lower gastrointestinal bleeding, angiodysplasia, esophageal varices and peptic ulcer disease is a key factor driving the submucosal lifting agent market. As the prevalence of disorders such as gastrointestinal bleeding, polyps, and tumors rises, so does the demand for endoscopic operations that require submucosal lifting agents.
According to the article published in Stat Pearls Journal on June 2023, UGIB (Upper gastrointestinal bleeding) affects roughly 67/100,000 people, and LGIB (Lower Gastrointestinal Bleeding) affects around 36/100,000 people.
These chemicals form a barrier between tissue layers, allowing for better imaging and treatment. The growing prevalence of gastrointestinal illnesses emphasizes the significance of precise diagnosis and minimally invasive therapies, which supports the use of submucosal lifting agents.
The emphasis on early identification and treatment by healthcare professionals amplifies the importance of these agents, positioning the market for growth as they play a crucial role in enhancing procedure results and patient care.
Principal Consultant
Due to high costs and a scarcity of trained practitioners, the submucosal lifting agent industry faces growth limits. These agent’s development and production costs can raise procedure prices, limiting availability for patients and healthcare facilities.
Likewise, specialized training is essential for practitioners to execute endoscopic procedures with these agents competently, but a dearth of appropriately qualified experts impedes widespread implementation. These constraints hamper market expansion by discouraging potential users from adopting the technology and preventing the incorporation of submucosal lifting agents into ordinary medical practices.
Addressing these problems through cost-effective solutions and thorough training programs is critical to realizing this market's full growth potential.
Market Growth Outlook by Key Countries
| Countries | Value CAGR |
|---|---|
| United States | 6.8% |
| Germany | 7.9% |
| United Kingdom | 6.3% |
| Japan | 6.0% |
| China | 7.2% |
| India | 10.0% |
The United States dominates the global market with 38.0% market share in 2022 and is projected to continue experiencing high growth throughout the forecast period. The increased prevalence of gastrointestinal illnesses in the United States, especially colorectal cancer, drives the demand for submucosal lifting agents. These medicines are required for safer and more successful tumor resections and interventions during endoscopic operations.
As the incidence of colorectal cancer rises, so does the demand for precise diagnoses and least invasive therapies. Submucosal lifting agents make these surgeries easier and improve patient outcomes. The rising prevalence of gastrointestinal disorders emphasizes the significance of modern medical instruments, positioning the submucosal lifting agent market in the United States for growth.
Germany held about 6.7% share of the global market in 2022 and is projected to increase during the forecast period. Germany presents a leading market for submucosal lifting agents due to the high demand for advanced endoscopic procedures like endoscopic submucosal dissection (ESD). While Germany achieves impressive en bloc resection rates with ESD, curative resection rates remain moderate.
ESD necessitates expertise and varies based on case volume at different centers. The establishment of a multicenter registry highlights the nation's commitment to evaluating and enhancing ESD's technical success, curative rates, long-term outcomes, and economic viability. With limited European ESD data, Germany's focus on quality improvement in this domain makes it a promising market for effective submucosal lifting agents.
United Kingdom held 6.1% of the global market share in 2022. The submucosal lifting agent market is thriving in the UK due to the rising adoption of endoscopic submucosal dissection (ESD) for gastrointestinal high-grade intramucosal neoplasia and superficially invasive cancer. ESD's en bloc resection offers improved completeness of excision assessment and a lower risk of recurrence for benign lesions.
While piecemeal endoscopic mucosal resection (pEMR) remains favored by some, the benefits of ESD often outweigh drawbacks. The surge in the submucosal lifting agent market is attributed to the growing recognition of ESD's advantages and a shift towards incorporating this advanced technique into local and regional practices.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Market Growth Outlook by Key Ingredients
| Ingredients | Value CAGR |
|---|---|
| Poloxamer 188 and Polyoxyl-15-hydroxystearate | 4.5% |
| Gellan Gum and Polysaccharide | 5.0% |
| Sodium Hyaluronate | 7.5% |
| Cellulose | 6.6% |
| Absorbable Starch Polymers | 7.8% |
| Poloxamers | 9.0% |
Sodium hyaluronate within the ingredient segment hold a revenue share of 28.4% in 2022, and the same trend is being followed over the forecasted period. Sodium hyaluronate is extensively used in the submucosal lifting agent market. As a naturally occurring glycosaminoglycan, it plays a pivotal role in wound healing, inflammation, and development.
Its viscoelastic properties make it a prime choice in ophthalmic applications, protecting the corneal endothelium and maintaining anterior chamber depth during intraocular surgery.
Recent animal experiments reveal its potential in promoting corneal epithelial wound healing by stimulating cell migration, adhesion, and proliferation. Acting as a ligand for CD44, sodium hyaluronate's involvement in cell interactions and migration during re-epithelialization underscores its significance in the submucosal lifting agent market.
Market Growth Outlook by Key Applications
| Applications | Value CAGR |
|---|---|
| Polyps | 5.6% |
| Adenomas | 8.4% |
| Early-stage Cancers | 7.4% |
| Gastrointestinal Mucosal Lesions | 8.7% |
| Others | 5.1% |
Early-stage cancers held a market share of 32.7% in 2022. In the Submucosal Lifting Agent Market, a dominant application is the management of early-stage cancers within the gastrointestinal tract.
Submucosal injection of lifting agent’s aids in endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), techniques used for excising neoplasms confined to the mucosa or submucosa. This technique cushions polyps, adenomas, and early-stage cancers, enabling effective excision.
Synthetic agents like Eleview® and ORISE® have gained popularity due to extended submucosal fluid maintenance, reducing procedure times. ORISE® notably triggers a foreign body-type giant cell reaction, known as 'lifting agent granuloma.' These advancements underscore submucosal lifting agents' role in minimally invasive, effective early-stage cancer removal within the gastrointestinal tract.
Market Growth Outlook by Key End Users
| End Users | Value CAGR |
|---|---|
| Hospitals | 6.7% |
| Specialty Clinics | 6.2% |
| Surgical Centers | 7.9% |
| Others | 7.4% |
Hospitals held a market share of 37.0% in 2022. Given their role as key locations for surgical procedures, hospitals dominate the end-user segment of the submucosal lifting agent market. The regulated environment, the availability of experienced medical professionals, and the necessity for sophisticated surgical equipment drive the need for submucosal lifting agents.
The fact that hospitals have a large caseload and a focus on patient outcomes solidifies their position as the major users of these novel surgical instruments.
Leading submucosal lifting agent manufacturers prioritize strategic collaborations as they attempt to develop new product lines and increase their global consumer base.
Related Market Growth Outlook Scenario
| Particulars | Value CAGR |
|---|---|
| Gastroesophageal Reflux Disease (GERD) Devices Market | 4.0% |
| Gastroesophageal Junction Adenocarcinoma Therapeutics Market | 18.0% |
| Gastrointestinal Stromal Tumor (GIST) Therapeutics Market | 6.0% |
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East and Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, South Africa, and Northern Africa |
| Key Market Segments Covered | Ingredient, Application, End User and Region |
| Key Companies Profiled | Laborie; STERIS; Olympus America; Medtronic; Boston Scientific Corporation; Omnimed Ltd™; COSMO PHARMACEUTICALS; Micro-Tech Endoscopy; Ovesco Endoscopy AG |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The global market is currently valued at around USD 106.9 million in 2022.
The global estimate for 2023 is around USD 114.2 million.
The global market is set to reach a valuation of around USD 222.6 million by 2033.
Sales of the market are set to witness growth at a CAGR of 6.9% between 2023 and 2033.
Demand for the global market increased at a 6.4% CAGR from 2017 to 2022.
The United States, Germany, United Kingdom, Japan and Australia account for most demand within the market, currently holding around 59.5% market share.
The United States accounts for around 38.0% share of the global market in 2022.
The Germany market held a share of about 20.4% in the European market in 2022.
United Kingdom accounts for around 6.1% share of the global market in 2022.
Early-stage cancers segment held 32.7% share of the global market in 2022.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Value Added Insights 5. Market Background 6. Global Market Demand (in Volume) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market - Pricing Assessment 8. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Ingredient 9.1. Poloxamer 188 and Polyoxyl-15-hydroxystearate 9.2. Gellan gum and Polysaccharide 9.3. Sodium hyaluronate 9.4. Cellulose 9.5. Absorbable starch polymers 9.6. Poloxamers 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 10.1. Polyps 10.2. Adenomas 10.3. Early-stage cancers 10.4. Gastrointestinal mucosal lesions 10.5. Others 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 11.1. Hospitals 11.2. Specialty Clinics 11.3. Surgical Centers 11.4. Others 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. South Asia 12.5. East Asia 12.6. Oceania 12.7. Middle East and Africa 13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 20. Market Structure Analysis 21. Competition Analysis 21.1. Laborie 21.2. STERIS 21.3. Olympus America 21.4. Medtronic 21.5. Boston Scientific Corporation 21.6. Omnimed Ltd™ 21.7. COSMO PHARMACEUTICALS 21.8. Micro-Tech Endoscopy 21.9. Ovesco Endoscopy AG 22. Assumptions and Acronyms Used 23. Research Methodology
Healthcare
February 2023
REP-GB-16670
288 pages
Explore Healthcare Insights
View Reports
Submucosal Lifting Agent Market
